Historique
Auteur A. COUSIEN
Documents disponibles écrits par cet auteur (4)
Ajouter le résultat à votre sélection Affiner la recherche
A. COUSIEN ; C. DONADILLE ; L. BRIAND MADRID ; G. MARADAN ; M. JAUFFRET-ROUSTIDE ; L. LALANNE ; M. AURIACOMBE ; P. ROUX ; S. BOYER | 2024
Dans BMC Public Health (Vol.24, 2024) Article : PériodiqueBackground: People who inject drugs (PWID) experience many health problems which result in a heavy economic and public health burden. To tackle this issue, France opened two drug consumption rooms (DCRs) in Paris and Strasbourg in 2016. This stu[...]
A. COUSIEN ; V. C. TRAN ; S. DEUFFIC-BURBAN ; M. JAUFFRET-ROUSTIDE ; J. DHERSIN ; Y. YAZDANPANAH | 2015
Dans Journal of Viral Hepatitis (Vol.22, n°3, March 2015) Article : PériodiqueEquipment sharing among people who inject drugs (PWID) is a key risk factor in infection by hepatitis C virus (HCV). Both the effectiveness and cost-effectiveness of interventions aimed at reducing HCV transmission in this population (such as op[...]
A. COUSIEN ; V. C. TRAN ; S. DEUFFIC-BURBAN ; M. JAUFFRET-ROUSTIDE ; G. MABILEAU ; J. S. DHERSIN ; Y. YAZDANPANAH | 2018
Dans Journal of Viral Hepatitis (Vol.25, n°10, October 2018) Article : PériodiqueDirect-acting antivirals (DAAs) represent an opportunity to improve hepatitis C virus (HCV) care cascade. This, combined with improved harm reduction interventions may lead to HCV elimination especially in people who inject drugs (PWID). We asse[...]
A. COUSIEN ; V. C. TRAN ; S. DEUFFIC-BURBAN ; M. JAUFFRET-ROUSTIDE ; J. S. DHERSIN ; Y. YAZDANPANAH | 2016
Dans Hepatology (Vol.63, n°4, April 2016) Article : PériodiqueBackground: Hepatitis C virus (HCV) seroprevalence remains high in people who inject drug (PWID) populations, often above 60%. Highly effective direct-acting antiviral (DAA) regimens (90% efficacy) are becoming available for HCV treatment. This [...]
